Citations

Clear

10 citation(s) found for "Sciacca, E".

miR-205-5p drives endothelial dysfunction and senescence in pulmonary fibrosis
Roos, B., Harris, Sharonda, Civettini, Gina, Sciacca, Enrico, Raslan, A, Elliot, Sharon, Glassberg, Marilyn K. , Vancheri, Carlo, Tschumperlin, Daniel J. , Ligresti, Giovanni , Raslan, Ahmed , Muscato, Giuseppe , Cai, Xiaoyu Tracy , Castaldi, Alessandra , Vancheri, Carlo , Caporarello, Nunzia

Mayo Clinic

JCI Insight | May 28, 2026 | Volume: 11 | Issue: 13 | Pages: No page available

10.1172/jci.insight.201842 | PMID 42207587 Get It

Idiopathic pulmonary fibrosis (IPF) is a fatal, aging-related disease characterized by persistent lung fibroblast activation, progressive lung scarring, and several vascular abnormalities. We have previously demonstrated that aging-associated vascular dysfunction drives maladaptive endothelial responses to injury and exacerbates lung fibrosis via secretion of profibrotic endothelial cell–derived factors. However, regulatory mechanisms governing endothelial dysfunction during progressive lung fibrosis remain poorly understood. Here, using preclinical mouse models of progressive lung fibrosis as well as human IPF lungs, we demonstrate that miR-205-5p was overexpressed in lung endothelial cells (ECs) from fibrotic lungs and coordinated gene expression programs implicated in endothelial dysfunction and progressive fibrosis. Mechanistically, miR-205-5p induced senescence in lung ECs, mirroring the senescent phenotype of IPF lung ECs. Consistently, conditioned medium derived from lung ECs overexpressing miR-205-5p promoted lung fibroblast activation. Importantly, miR-205-5p inhibition in IPF lung ECs attenuated endothelial senescence and limited paracrine fibroblast activation. Finally, inhibition of miR-205-5p in vivo preserved the pulmonary vascular network and attenuated lung fibrosis progression in aged mice challenged with bleomycin. Collectively, our findings support what we believe to be a novel connection among lung endothelial miR-205-5p, endothelial senescence, and profibrotic alteration of the endothelial secretome and highlight miR-205-5p inhibition as a potential therapeutic intervention for pulmonary fibrosis.
A109-22 When the Pulmonary Endothelium Speaks: Circulating Extracellular Vesicles as Messengers of Pulmonary Fibrosis Progression in Patients With Scleroderma?
Sciacca, E, Roos, B B, Muscato, G, Sambatro, G, Vancheri, C, Csete, M K Glassberg, Ligresti, G, Tschumperlin, D J, Porquera, E M Carmona, Javeed, N, Hinze, A M, Caporarello, N, Sciacca, Enrico, Roos, B., Muscato, Giuseppe , Glassberg, Marilyn K. , Ligresti, Giovanni , Porquera, Eva M. Carmona, Javeed, Naureen , Hinze, Alicia M. , Caporarello, Nunzia

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.2422 Get It

Abstract Rationale Systemic sclerosis (SSc) is a rare, chronic autoimmune disease characterized by vasculopathy and fibrosis of the skin and internal organs. Among its manifestations, interstitial lung disease (ILD) is the leading cause of mortality, yet its clinical course is variable, ranging from stable to progressive pulmonary fibrosis (PPF). The 2022 ATS/ERS/JRS/ALAT guidelines defined progressive PPF as a phenotype of non- Idiopathic Pulmonary Fibrosis (IPF) - ILDs that behave similarly to IPF. Although a subset of SSc-ILD patients develop PPF, biomarkers predicting progression remain lacking. We and others have shown that endothelial dysfunction contributes to the progression of fibrotic lung disease, and that the pulmonary vasculature, continuously exposed to the bloodstream, is influenced by soluble circulating factors, including circulating extracellular vesicles (cEVs), which carry bioactive cargo capable of modulating endothelial behavior. Here, we investigated whether cEVs from SSc patients with distinct fibrotic phenotypes differentially influence human lung endothelial cells (ECs), promoting a pro-fibrotic endothelial phenotype. Methods plasma samples were collected from five groups: 1) Healthy controls (n = 4); 2) SSc-noILD (no high-resolution-CT (HCRT( or functional evidence of ILD at time of enrollment, n = 4); 3) SSc-ILD (HCRT and functional evidence of ILD without meeting the PPF criteria at time of sampling, n = 3); 4) SSc-PPF (meeting the PPF criteria, plasma collected prior to anti-fibrotic therapy, n = 4); 5) IPF (plasma collected prior to anti-fibrotic therapy, n = 3). cEVs were isolated using size-exclusion-chromatography and characterized using Nanoparticle Tracking Analysis (NTA). Human lung ECs were treated with cEVs from the five groups (2x109 particles/ml, 48 hours), followed by qPCR for markers selected for their established involvement in endothelial dysfunction during lung fibrotic progression. Results NTA showed no significant differences in plasma cEV concentrations across the five groups. Human lung ECs exposed to cEVs from SSc or SSc-ILD patients exhibited no significant gene expression changes compared to healthy controls. In contrast, cEVs from SSc-PPF patients markedly downregulated endothelial identity (PECAM1, ERG, TEK), barrier integrity (CDH13, S1PR1), and basement membrane (COL4A1, HSPG2) genes, similarly to changes induced by cEVs from IPF patients. Conclusion cEVs from SSc-PPF patients induce pro-fibrotic transcriptional changes in lung ECs resembling those induced by IPF cEVs and distinct from SSc-ILD cEVs, suggesting that EVs carry cargo that both reflect and influence fibrosis progression. These findings highlight the potential of cEVs as biomarkers for identifying SSC-ILD patients at risk of progression and highlight the clinical relevance of future studies aimed at characterizing their cargo. This abstract is funded by: James Depauw Grant for Pilot Projects
Vascular protection by young circulating extracellular vesicles ameliorates aging-related pulmonary fibrosis
Gianì, Fiorenza , Roos, B., Link, Patrick A. , Somasundram, Bharath , Dresler, Sara R. , Sciacca, Enrico, Javeed, Naureen , Ligresti, Giovanni , Tschumperlin, Daniel J. , Tschumperlin, Daniel J , Caporarello, Nunzia , Link, Patrick A , Vancheri, Carlo , Caporarello, Nunzia

Mayo Clinic

American Journal of Physiology-Cell Physiology | May 24, 2025 | Volume: 329 | Issue: 1 | Pages: C159-C169

10.1152/ajpcell.00022.2025 | PMID 40411768 Get It

This study demonstrates that circulating extracellular vesicles (cEVs) isolated from young mice reverse the transcriptional alterations of the aged mouse pulmonary vasculature, leading to a more youthful endothelial transcriptional phenotype. As a result of this vascular phenotype, aged mice are protected from bleomycin-induced pulmonary fibrosis. These findings highlight the therapeutic potential of targeting vascular aging to alleviate pulmonary fibrosis.
Gaps and Knowledge in the Contemporary Management of Acute Right Ventricular Failure
Manca, Paolo , Mulè, Massimiliano , Sciacca, Sergio, Castrichini, Matteo , Pereira, Naveen L. , Thiele, Hölger , Jentzer, Jacob C. , Mulè, Massimiliano , Castrichini, Matteo , Pereira, Naveen L , Thiele, Holger , Jentzer, Jacob C , Cipriani, Manlio , Nuzzi, Vincenzo , Sciacca, Sergio , Schulz, Uwe

Mayo Clinic

Circulation: Heart Failure | May 13, 2025 | Volume: 18 | Issue: 9 | Pages: No page available

10.1161/circheartfailure.124.012030 | PMID 40223610 Get It

Acute right ventricular failure (ARVF) is commonly seen in the intensive care unit and constitutes a significant clinical challenge, with associated high in-hospital mortality. Recently, the treatment of ARVF has significantly changed, with the progressive implementation of mechanical circulatory support devices that now represent important tools for clinicians in treating this condition. However, despite recent advancements, the optimal approach for ARVF remains elusive, and precise treatment algorithms and comprehensive management protocols are still lacking. In the present review, we explore the pathophysiology of ARVF, highlighting the different mechanisms that may lead to this clinical entity and emphasizing the left and right heart’s complex interplay. We analyze the different therapeutic options that are now available for short- and long-term management of ARVF, with a particular focus on the advantages and disadvantages of the mechanical circulatory support devices actually used. Furthermore, we propose future directions in the field and a possible flowchart for the treatment of this condition.
Lung Endothelial MiR-205-5P Induces a Pro-fibrotic Endothelial Secretory State and Promotes Lung Fibroblast Activation
Roos, B., Elliot, S., Csete, M.K. Glassberg, Tschumperlin, Daniel J. , Ligresti, Giovanni , Muscato, Giuseppe , Sciacca, ‬‬‬‬‬‬Eva , Raslan, Ahmed , Vancheri, Carlo , Elliot, Sharon J. , Caporarello, Nunzia

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A4627-A4627

10.1164/ajrccm.2025.211.abstracts.a4627 Get It

Abstract RATIONALE: Vascular dysfunction contributes to pathological tissue remodeling in aging-associated disease such as Idiopathic Pulmonary Fibrosis (IPF). IPF is an incurable lung disease characterized by progressive accumulation of scar-forming fibroblasts and several vascular alterations, including endothelial transcriptional changes leading to a pro-fibrotic endothelial secretory phenotype. To date, the mechanisms governing these transcriptional changes remain largely unexplored. To fill this gap, we sought to investigate whether microRNAs (miRNAs), small non-coding RNA that function as key gene expression regulators, modulate the transcriptional changes of the endothelium associated with progressive pulmonary fibrosis. METHODS AND RESULTS: miRNA expression profiling of lung ECs (LECs) sorted from aged mice with persistent lung fibrosis revealed upregulation of miR-205-5p. Further analysis demonstrated that endothelial miR-205-5p was strongly upregulated in an additional mouse model of progressive lung fibrosis induced by repetitive bleomycin dose as well as in human LECs purified from IPF lungs. RNA-seq analysis of normal human LECs overexpressing miR-205-5p revealed reduction of genes associated to endothelial identity (e.g. PECAM1, ERG, NOS3), and an increase of genes encoding for soluble pro-inflammatory and pro-fibrotic molecules, including TGFBI, TGFB2, TGFB3, CXCL10, CCL5, IL1B and FAS compared to normal LECs transfected with a control mimic. Consistently, conditioned medium from miR-205-5p overxpressing LECs exerted a pro-fibrotic activity on quiescent human lung fibroblasts, as demonstrated by upregulation of a panel of profibrotic transcripts (e.g. COL1A1, CTHRC1, FN1 and TNC) and elevated Collagen I deposition compared to human lung fibroblasts exposed to conditioned medium generated by human LECs transfected with a control mimic. CONCLUSION: Altogether, our findings suggest that lung endothelail miR-205-5p induces loss of endothelial cell identity and drives the secretion of pro-fibrotic molecules that promote the transition of quiescent fibroblasts into scar-forming fibroblast through paracrine signal. Our data set the stage for further investigations into the role of miR-205-5p and associated pathways in lung vascular injury responses, with the long term goal of targeting endothelial dysfunction for slowing the progression of pulmonary fibrosis.
An Intervention to Increase Advance Care Planning Among Older Adults With Advanced Cancer
Volandes, Angelo E., Chang, Yuchiao , Paasche‐Orlow, Michael K. , Lindvall, Charlotta , Zupanc, Seth N., Martins-Welch, Diana , Carney, Maria Torroella , Burns, Edith , Itty, Jennifer, Emmert-Tangredi, Kaitlin, Martin, Narda J., Sanghani, Shreya, Tilburt, Jon C. , Davis, Aretha Delight , Garde, Cynthia, El‐Jawahri, Areej , Quintiliani, Lisa M. , Sciacca, Kate, Tulsky, James A. , Lakin, Joshua R. , Zupanc, Sophia N. , Pollak, Kathryn I. , Barry, Michael J. , Goldman, Julie

Mayo Clinic

JAMA Network Open | May 9, 2025 | Volume: 8 | Issue: 5 | Pages: e259150

10.1001/jamanetworkopen.2025.9150 | PMID 40343696 Get It

Importance Many older adults with advanced cancer never communicate goals of care or treatment preferences to their clinicians, raising the risk that care received will not match their values. Scalable models of care may help surmount this barrier. Objective To test whether a combined patient and clinician intervention increased the rate of advance care planning (ACP) documentation in large health care systems. Design, Setting, and Participants This stepped-wedge cluster randomized clinical trial using an open cohort design included patients aged 65 years or older with advanced cancer seen at oncology clinics in 3 health care systems located in the US South, Midwest, and Mid-Atlantic regions from April 1, 2020, to November 30, 2022. Data collection ended in 2024. Intervention The intervention involved delivering brief evidence-based patient-facing video decision aids available in 25 languages as well as goals-of-care communication training to oncology clinicians. Patients in the control period received usual care. Main Outcomes and Measures The primary outcome was ACP documentation, which included any electronic health record documentation of a goals-of-care conversation, palliative care, hospice, or limitation of life-sustaining treatments, identified via a validated natural language processing program. Analysis was performed on an intention-to-treat basis. Results Twenty-nine practices, comprising 13 800 unique eligible patients with a total of 29 357 repeated measurements, were included (mean [SD] age, 74.5 [6.6] years; 52.3% men [15 344 of 29 357 measurements]). The proportion of patients with ACP documentation was greater in the intervention phase compared with the usual care phase (adjusted rate difference, 6.8% [95% CI, 2.8%-10.8%]; P < .001). ACP documentation in the intervention phase occurred among 3980 of 15 754 patients (25.3%) (goals-of-care conversation, 21.4% [3377 of 15 754]; palliative care, 9.6% [1517 of 15 754]; hospice, 5.4% [847 of 15 754]; and limitation of life-sustaining treatments, 7.2% [1128 of 15 754]). In comparison, ACP documentation in the usual care phase occurred among 2834 of 13 603 patients (20.8%) (goals-of-care conversation, 16.8% [2281 of 13 603]; palliative care, 9.5% [1287 of 13 603]; hospice, 5.3% [724 of 13 603]; and limitation of life-sustaining treatments, 8.4% [1149 of 13 603]). Conclusions and Relevance In this stepped-wedge cluster randomized clinical trial for older adults with advanced cancer, a bundled evidence-based decision aid and communication training intervention increased the proportion of older patients with ACP documentation. This approach offers an innovative paradigm with a clinically meaningful increase in ACP documentation, a widely used quality metric that reflects high-quality patient-centered care delivery. Trial Registration ClinicalTrials.gov Identifier: NCT03609177
MicroRNA-30d and -483-3p for Bi-Ventricular Remodelling and miR-126-3p for Pulmonary Hypertension in Advanced Heart Failure
Sciacca, Sergio , Scardulla, Cesare, Cipriani, Manlio, Oh, Jae K. , Pasta, Salvatore , Maalouf, Joseph F., Bellavia, Diego , Pasta, Salvatore , Gallo, Alessia , Agnese, Valentina , Cipriani, Manlio , Pilato, Michele , Conaldi, Pier Giulio

Mayo Clinic

ESC Heart Failure | October 21, 2023 | Volume: 11 | Issue: 1 | Pages: 155-166

10.1002/ehf2.14546 | PMID 37864482 Get It

Abstract Aims MicroRNAs play a role in pathogenic mechanisms leading to heart failure. We measured a panel of 754 miRNAs in the myocardial tissue and in the serum of patients with heart failure with reduced ejection fraction due to dilatative idiopathic cardiomyopathy (DCM, N = 10) or ischaemic cardiomyopathy (N = 3), referred to left ventricular assist device implant. We aim to identify circulating miRNAs with high tissue co-expression, significantly associated to echocardiographic and haemodynamic measures. Methods and results We have measured a panel of 754 miRNAs in the myocardial tissue [left ventricular (LV) apex] and in the serum obtained at the same time in a well selected study population of end-stage heart failure with reduced ejection fraction due to either DCM or ischaemic cardiomyopathy, referred to continuous flow left ventricular assist device implant. We observed moderate agreement for miR-30d, miR-126-3p, and miR-483-3p. MiR-30d was correlated to LV systolic as well as diastolic volumes (r = 0.78, P = 0.001 and r = 0.80, P = 0.005, respectively), while miR-126-3p was associated to mPAP and PCWP (r = −0.79, P = 0.007 and r = −0.80, P = 0.005, respectively). Finally, serum miR-483-3p had an association with right ventricular end diastolic diameter (r = −0.73, P = 0.02) and central venous pressure (CVP) (r − 0.68 p 0.03). Conclusions In patients with DCM, few miRNAs are co-expressed in serum and tissue: They are related to LV remodelling (miR-30d), post-capillary pulmonary artery pressure (miR-126-3p), and right ventricular remodelling/filling pressures (miR-483-3p). Further studies are needed to confirm their role in diagnosis, prognosis or as therapeutic targets in heart failure with reduced ejection fraction.
Top Ten Tips Palliative Care Clinicians Should Know About Delivering Specialty-Aligned Palliative Care
Leiter, Richard E. , Bischoff, Kara , Carey, Elise C. , Gelfand, Samantha L. , Iyer, Anand , Jain, Nelia , Kramer, Neha M. , Lally, Kate , Landzberg, Michael J., Lever, Natasha, Newport, Kristina , O’Donnell, Arden , Sciacca, Kate, Snaman, Jennifer M. , Tulsky, James A. , Rosa, William E. , Bischoff, Kara E , Iyer, Anand S , Tulsky, James A , Rosa, William E , Patel, Arpan , Lakin, Joshua R.

Mayo Clinic

Journal of Palliative Medicine | March 31, 2023 | Volume: 26 | Issue: 10 | Pages: 1401-1407

10.1089/jpm.2023.0116 | PMID 37001173 Get It

Usefulness of regional right ventricular and right atrial strain for prediction of early and late right ventricular failure following a left ventricular assist device implant: A machine learning approach
Bellavia, Diego , Coronnello, Claudia , Pasta, Salvatore , Novo, Giuseppina , Maalouf, Joseph F., Sciacca, Sergio , Pilato, Michele , Clemenza, Francesco , Gorcsan, Sir. John, Pasta, Salvatore , Sciacca, Sergio , Iacovoni, Attilio , Agnese, Valentina , Falletta, Calogero , Gesaro, Gabriele Di , Senni, Michele , Simon, Marc A.

Mayo Clinic

The International Journal of Artificial Organs | December 13, 2019 | Volume: 43 | Issue: 5 | Pages: 297-314

10.1177/0391398819884941 | PMID 31830841 Get It

Background: Identifying candidates for left ventricular assist device surgery at risk of right ventricular failure remains difficult. The aim was to identify the most accurate predictors of right ventricular failure among clinical, biological, and imaging markers, assessed by agreement of different supervised machine learning algorithms. Methods: Seventy-four patients, referred to HeartWare left ventricular assist device since 2010 in two Italian centers, were recruited. Biomarkers, right ventricular standard, and strain echocardiography, as well as cath-lab measures, were compared among patients who did not develop right ventricular failure (N = 56), those with acute–right ventricular failure (N = 8, 11%) or chronic–right ventricular failure (N = 10, 14%). Logistic regression, penalized logistic regression, linear support vector machines, and naïve Bayes algorithms with leave-one-out validation were used to evaluate the efficiency of any combination of three collected variables in an “all-subsets” approach. Results: Michigan risk score combined with central venous pressure assessed invasively and apical longitudinal systolic strain of the right ventricular–free wall were the most significant predictors of acute–right ventricular failure (maximum receiver operating characteristic–area under the curve = 0.95, 95% confidence interval = 0.91–1.00, by the naïve Bayes), while the right ventricular–free wall systolic strain of the middle segment, right atrial strain (QRS-synced), and tricuspid annular plane systolic excursion were the most significant predictors of Chronic-RVF (receiver operating characteristic–area under the curve = 0.97, 95% confidence interval = 0.91–1.00, according to naïve Bayes). Conclusion: Apical right ventricular strain as well as right atrial strain provides complementary information, both critical to predict acute–right ventricular failure and chronic–right ventricular failure, respectively.
Independent Effects of Hypertension and Obesity on Left Ventricular Mass and Geometry: Evidence from the Cardiovision 2030 Study
Maugeri, Andrea , Hrusková, J , Jakubík, Juraj , Barchitta, Martina , Re, Oriana Lo , Medina‐Inojosa, José R. , Agodi, Antonella , Sciacca, Sergio, Vinciguerra, Manlio , Medina-Inojosa, Jose R., Vinciguerra, Manlio , Medina-Inojosa, José R , Kunzová, Šárka , Sciacca, Sergio

Mayo Clinic

Journal of Clinical Medicine | March 18, 2019 | Volume: 8 | Issue: 3 | Pages: 370

10.3390/jcm8030370 | PMID 30884768 Get It

Obesity and hypertension independently promote pathological left ventricular remodelling (LVR) and left ventricular hypertrophy (LVH), but to what extent they do so when they do not coexist is unclear. We used data from the Cardiovision Brno 2030 study to assess—for the first time in a region where no investigations have been previously carried out—the independent association of obesity and hypertension with LV geometry, and to evaluate the effects of hypertension in normal weight patients and the effects of obesity in normotensive patients. Overall, 433 individuals, aged 25–65 years, with no history of cardiovascular disease and/or antihypertensive treatment, were stratified into four groups according to BMI and hypertension: normal weight non-hypertensive (NWNH), normal weight hypertensive (NWH), overweight/obese non-hypertensive (ONH) and overweight/obese hypertensive (OH). LVR was classified as normal, concentric LVR (cLVR), concentric LVH (cLVH) or eccentric LVH (eLVH). Linear regression analysis demonstrated that body mass index (BMI) and systolic blood pressure (SBP) are the main predictors of LV mass and that they interact: SBP had a stronger effect in overweight/obese (β = 0.195; p = 0.033) compared to normal weight patients (β = 0.134; p = 0.048). Hypertension increased the odds of cLVR (OR = 1.78; 95%CI = 1.04–3.06; p = 0.037) and cLVH (OR = 8.20; 95% CI = 2.35–28.66; p = 0.001), independent of age, sex and BMI. Stratified analyses showed that NWH had a greater odd of cLVH (OR = 7.96; 95%CI = 1.70–37.08; p = 0.008) and cLVR (OR = 1.62; 95%CI = 1.02–3.34; p = 0.047) than NWNH. In the absence of hypertension, obesity was not associated with LVM and abnormal LV geometry, suggesting that it is not per se a determinant of LVR. Thus, antihypertensive therapy still remains the first-line approach against LVH in hypertensive patients, though weight loss interventions might be helpful in those who are obese.